Arthritis, Rheumatoid Clinical Trial
— ARABESCOfficial title:
A Randomised, Blinded, Active-Controlled Study to Compare FKB327 Efficacy and Safety With the Comparator Humira® in Rheumatoid Arthritis Patients Inadequately Controlled on Methotrexate
Verified date | October 2017 |
Source | Fujifilm Kyowa Kirin Biologics Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to compare the effectiveness and safety of FKB327 in comparison to Humira® in rheumatoid arthritis patients who have inadequate disease control on methotrexate.
Status | Completed |
Enrollment | 728 |
Est. completion date | July 2016 |
Est. primary completion date | July 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Male or female aged 18 years or over 2. Patients have been diagnosed with Rheumatoid Arthritis (RA) for at least 3 months 3. Patient has active RA 4. Patient has taken a stable dose of methotrexate for at least 3 months Exclusion Criteria: 1. Patient has been previously treated with adalimumab 2. Patient has been previously treated or has ongoing treatment with prohibited medications 3. Patient has been immunised with a live or attenuated vaccine in past 4 weeks 4. Patient has positive result for HIV, HBV, HCV or TB infection Other Inclusion/Exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Bulgaria | Research Site | Plovdiv | |
Bulgaria | Research Site | Sofia | |
Canada | Research Site | Mississauga | Ontario |
Canada | Research Site | St. Catherines | Ontario |
Canada | Research Site | Trois-Rivieres | Quebec |
Chile | Research Site | Osorno | |
Chile | Research Site | Puerto Varas | |
Chile | Research Site G | Santiago | |
Chile | Research Site M | Santiago | |
Chile | Research Site | Temuco | |
Czechia | Research Site | Brno | |
Czechia | Research Site | Hlucin | |
Czechia | Research Site | Prague | |
Czechia | Research Site U | Prague | |
Czechia | Research Site | Uherske Hradiste | |
Czechia | Research Site | Zlin | |
Germany | Research Site | Aachen | |
Germany | Research Site | Berlin | |
Germany | Research Site | Hamburg | |
Germany | Research Site | Hildesheim | |
Germany | Research Site | Munich | |
Germany | Research Site | Ratingen | |
Peru | Research Site B | Arequipa | |
Peru | Research Site M | Arequipa | |
Peru | Research Site CA | Lima | |
Peru | Research Site CH | Lima | |
Peru | Research Site PA | Lima | |
Peru | Research Site PE | Lima | |
Peru | Research Site S | Lima | |
Poland | Research Site D | Bialystok | |
Poland | Research Site R | Bialystok | |
Poland | Research Site | Gdynia | |
Poland | Research Site | Katowice | |
Poland | Research Site KL | Krakow | |
Poland | Research Site KR | Krakow | |
Poland | Research Site | Lublin | |
Poland | Research Site P | Poznan | |
Poland | Research Site RH | Poznan | |
Poland | Research Site | Torun | |
Romania | Research Site | Braila | |
Romania | Research Site | Brasov | |
Romania | Research Site C | Bucharest | |
Romania | Research Site R | Bucharest | |
Romania | Research Site T | Bucharest | |
Romania | Research Site | Constanta | |
Romania | Research Site | Galati | |
Romania | Research Site | Oradea | Bihor |
Romania | Research Site | Sfântu Gheorghe | |
Russian Federation | Research Site | Kazan | Tatarstan Republic |
Russian Federation | Research Site D | Moscow | |
Russian Federation | Research Site SM | Moscow | |
Russian Federation | Research Site ST | Moscow | |
Russian Federation | Research Site | Nizhny Novgorod | |
Russian Federation | Research Site | Penza | |
Russian Federation | Research Site | Perm | |
Russian Federation | Research Site | Petrozavodsk | Karelia Republic |
Russian Federation | Research Site | Ryazan | |
Russian Federation | Research Site B | Saint-Petersburg | |
Russian Federation | Research Site Z | Saint-Petersburg | |
Russian Federation | Research Site | Saratov | |
Russian Federation | Research Site | Smolensk | |
Russian Federation | Research Site | Ufa | Bashkortostan Republic |
Russian Federation | Research Site | Vladimir | |
Russian Federation | Research Site E | Yaroslavl | |
Russian Federation | Research Site S | Yaroslavl | |
Spain | Research Site A | Barcelona | |
Spain | Research Site G | Barcelona | |
Spain | Research Site | Bilbao | Vizcaya |
Spain | Research Site | Malaga | |
Spain | Research Site | Santiago de Compostela | La Coruna |
Ukraine | Research Site | Chernivtsi | |
Ukraine | Research Site | Ivano-Frankivsk | |
Ukraine | Research Site A | Kyiv | |
Ukraine | Research Site B | Kyiv | |
Ukraine | Research Site P | Kyiv | |
Ukraine | Research Site | Lutsk | |
Ukraine | Research Site C | Lviv | |
Ukraine | Research Site N | Lviv | |
Ukraine | Research Site | Poltava | |
Ukraine | Research Site | Ternopil | |
Ukraine | Research Site | Uzhgorod | |
Ukraine | Research Site G | Vinnytsia | |
Ukraine | Research Site Sh | Vinnytsia | |
Ukraine | Research Site St | Vinnytsia | |
United States | Research Site | Amarillo | Texas |
United States | Research Site | Austin | Texas |
United States | Research Site | Boca Raton | Florida |
United States | Research Site | Brandon | Florida |
United States | Research Site | Duncansville | Pennsylvania |
United States | Research Site | Durham | North Carolina |
United States | Research Site | Jacksonville | Florida |
United States | Research Site | Lansing | Michigan |
United States | Research Site | Mesquite | Texas |
United States | Research Site | Miami | Florida |
United States | Research Site | Miami Lakes | Florida |
United States | Research Site | Middleburg Heights | Ohio |
United States | Research Site | Palm Desert | California |
United States | Research Site | Peoria | Arizona |
United States | Research Site | Sarasota | Florida |
United States | Research Site | Shreveport | Louisiana |
Lead Sponsor | Collaborator |
---|---|
Fujifilm Kyowa Kirin Biologics Co., Ltd. |
United States, Bulgaria, Canada, Chile, Czechia, Germany, Peru, Poland, Romania, Russian Federation, Spain, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Percentage of Patients Developing Anti-drug Antibodies (ADAs) | Blood samples for the assessment of ADA activity were collected at Baseline (Week 0), prior to dosing at Weeks 2, 4, 12, and 24. | Baseline and last sampling day | |
Other | Trough Adalimumab Concentration | Blood samples for the quantification of adalimumab concentration in serum were collected at Baseline (Week 0), prior to dosing at Weeks 2, 4, 12 and 20, and Week 24. Samples were taken prior to dosing (trough samples). | Week 2, Week 4, Week 12, Week 20, and Week 24 | |
Primary | American College of Rheumatology (ACR) 20 Response Rate | The primary efficacy endpoint was the ACR20 response rate at Week 24. An ACR20 response meant that the patient achieved a 20% improvement in Tender Joint Count and Swollen Joint Count and in at least 3 of the other 5 Core Data Set elements listed below. Acute phase reactant (CRP) Patient global assessment of disease activity Physician global assessment of disease activity Patient pain scale Disability/functional questionnaire (patient completed Health Assessment Questionnaire Disability Index [HAQ-DI]) |
Week 24 | |
Secondary | Disease Activity Score 28 (DAS28) Based on C-reactive Protein (DAS28-CRP) Score | The DAS28-CRP assessment involved evaluating the number of tender (TJC) and swollen (SJC) joints (out of 28 specified joints), serum CRP, and patient global assessment of disease activity (VAS from 0 to 100, very well to extremely bad). The DAS28-CRP is a number on a scale from 0 to 10 indicating the current activity of the patient's RA. A higher score indicates higher disease activity. | Baseline, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24 | |
Secondary | ACR20 Response Rates Over Time | An ACR20 response meant that the patient achieved a 20% improvement in Tender Joint Count and Swollen Joint Count and in at least 3 of the other 5 Core Data Set elements listed below. Acute phase reactant (CRP) Patient global assessment of disease activity Physician global assessment of disease activity Patient pain scale Disability/functional questionnaire (patient completed Health Assessment Questionnaire Disability Index [HAQ-DI]) |
Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24 | |
Secondary | ACR50 Response Rates Over Time | An ACR50 response meant that the patient achieved a 50% improvement in Tender Joint Count and Swollen Joint Count and in at least 3 of the other 5 Core Data Set elements listed below. Acute phase reactant (CRP) Patient global assessment of disease activity Physician global assessment of disease activity Patient pain scale Disability/functional questionnaire (patient completed Health AssessmentQuestionnaire Disability Index [HAQ-DI]) |
Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24 | |
Secondary | ACR70 Response Rates Over Time | An ACR70 response meant that the patient achieved a 70% improvement in Tender Joint Count and Swollen Joint Count and in at least 3 of the other 5 Core Data Set elements listed below. Acute phase reactant (CRP) Patient global assessment of disease activity Physician global assessment of disease activity Patient pain scale Disability/functional questionnaire (patient completed Health AssessmentQuestionnaire Disability Index [HAQ-DI]) |
Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24 | |
Secondary | Swollen Joint Count | Counts of swollen joints from amongst 66 selected joints performed by a trained and qualified joint assessor using standardised techniques recommended by the European League Against Rheumatism (EULAR). Joints were classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66 with higher scores indicating severe disease. Swollen joint count is a value of the individual ACR core set variables. | Baseline and Week 24 | |
Secondary | Tender Joint Count | Counts of tender joints from amongst 68 selected joints were performed by a trained and qualified joint assessor using standardised techniques recommended by the European League Against Rheumatism (EULAR). Joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68 with higher scores indicating severe disease.Tender joint count is a value of the individual ACR core set variables. | Baseline and Week 24 | |
Secondary | Analysis of Serum C-Reactive Protein (CRP) Concentration | Analysis of serum C-Reactive Protein (CRP) concentrations for inclusion in the ACR20/50/70 and DAS28-CRP scores was performed by a central laboratory. Elevation of CRP is a nonspecific marker of inflammation. Values above 10 mg/L were considered to be abnormally high. Decrease in level of CRP indicates reduction in inflammation. | Baseline and Week 24 | |
Secondary | Patient Assessment of Disease Activity | Patient assessment of disease activity visual analogue scale (VAS) will be assessed on 100-point scales (ranging from very well (0) to extremely bad (100)).The patient assessment of disease activity VAS will contribute to the calculation of the DAS28 score. The patient assessment of disease activity VAS will contribute to the calculation of ACR20, ACR50 and ACR70 response. | Baseline and Week 24 | |
Secondary | Physician Assessment of Disease Activity | Physician assessment of disease activity visual analogue scale (VAS) will be assessed on 100-point scale (ranging from very low (0) to very high (100)). The physician assessment of disease activity VAS will contribute to the calculation of ACR20, ACR50 and ACR70 response. | Baseline and Week 24 | |
Secondary | Patient's Assessment of Pain | An injection site pain visual analogue score (VAS) will be administered to the patient. To determine the extent of the pain, patients will be asked to place a small vertical mark on a horizontal scale from 0 to 100, the ends of which are labelled with the extreme responses to be measured ("No pain" at 0 and "Intolerable pain" at 100). Patient's assessment of pain is a value of the individual ACR core set variables. | Baseline and Week 24 | |
Secondary | Health Assessment Questionnaire Disability Index (HAQ-DI) | The HAQ-DI is a 20-question, self-administered instrument that measures the patient's functional ability on a 4-level difficulty scale (0 to 3, with 0 representing normal or no difficulty and 3 representing inability to perform). Eight categories of functioning are included: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. This scale is sensitive to change and is a good predictor of future disability. HAQ-DI is a value of the individual ACR core set variables. | Baseline and Week 24 | |
Secondary | DAS28-CRP Score Over Time | The DAS28 score is a combined index that has been developed to measure the disease activity in patients with RA and has been extensively validated for its use in clinical studies. The DAS28-CRP assessment involved evaluating the number of tender (TJC) and swollen (SJC) joints (out of 28 specified joints), serum CRP, and patient global assessment of disease activity (VAS from 0 to 100, very well to extremely bad). The individual results are summed using a formula. The DAS28 is a number on a scale from 0 to 10 indicating the current activity of the patient's RA. A higher score indicates higher disease activity. | Baseline and Week 24 | |
Secondary | DAS28 Score Based on Erythrocyte Sedimentation Rate (DAS28-ESR) | The DAS28 score is a combined index that has been developed to measure the disease activity in patients with RA and has been extensively validated for its use in clinical studies. The DAS28-ESR assessment involved evaluating the number of tender (TJC) and swollen (SJC) joints (out of 28 specified joints), serum ESR, and patient global assessment of disease activity (VAS from 0 to 100, very well to extremely bad). The individual results are summed using a formula. The DAS28 is a number on a scale from 0 to 10 indicating the current activity of the patient's RA. A higher score indicates higher disease activity. | Baseline, Week 12 and Week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 | |
Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 |